You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

~ Buy the VIZIMPRO (dacomitinib) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR VIZIMPRO


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for VIZIMPRO

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03878524 ↗ Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Recruiting Oregon Health and Science University Phase 1 2020-04-01 This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has. This study is also being done to understand why cancer drugs can stop working and how different cancers in different people respond to different types of therapy.
NCT03878524 ↗ Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Recruiting Prospect Creek Foundation Phase 1 2020-04-01 This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has. This study is also being done to understand why cancer drugs can stop working and how different cancers in different people respond to different types of therapy.
NCT03878524 ↗ Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Recruiting OHSU Knight Cancer Institute Phase 1 2020-04-01 This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has. This study is also being done to understand why cancer drugs can stop working and how different cancers in different people respond to different types of therapy.
NCT04027647 ↗ Phase 2 Study of Dacomitinib in NSCLC Recruiting Pfizer Phase 2 2019-09-11 This is a multi-national, multi-centre, single-arm, open-label, Phase 2 clinical study of the efficacy and safety of first-line treatment with dacomitinib, with or without dose titration, in subjects with newly diagnosed stage IIIB/IIIC/IV or recurrent EGFR-mutation-positive non-small cell lung cancer (NSCLC). National Cancer Centre Singapore is the lead sponsor acting in a coordinating capacity and the rest of the participating sites are sponsors of their own individual sites.
NCT04027647 ↗ Phase 2 Study of Dacomitinib in NSCLC Recruiting National Cancer Centre, Singapore Phase 2 2019-09-11 This is a multi-national, multi-centre, single-arm, open-label, Phase 2 clinical study of the efficacy and safety of first-line treatment with dacomitinib, with or without dose titration, in subjects with newly diagnosed stage IIIB/IIIC/IV or recurrent EGFR-mutation-positive non-small cell lung cancer (NSCLC). National Cancer Centre Singapore is the lead sponsor acting in a coordinating capacity and the rest of the participating sites are sponsors of their own individual sites.
NCT04423185 ↗ PLATFORM Study of Precision Medicine for Rare Tumors Not yet recruiting Cancer Institute and Hospital, Chinese Academy of Medical Sciences Phase 2 2020-08-15 A Phase II, open label, non-randomized, multiple-arm, single-center clinical trial in patients with advanced rare solid tumors who failed to standard treatment.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for VIZIMPRO

Condition Name

Condition Name for VIZIMPRO
Intervention Trials
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable 1
Refractory Myelodysplastic Syndrome 1
Recurrent Acute Lymphoblastic Leukemia 1
Stage IV Prostate Cancer AJCC v8 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for VIZIMPRO
Intervention Trials
Carcinoma, Non-Small-Cell Lung 3
Neoplasms 2
Lung Neoplasms 2
Pancreatic Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for VIZIMPRO

Trials by Country

Trials by Country for VIZIMPRO
Location Trials
Italy 16
Korea, Republic of 2
Malaysia 2
Thailand 1
Taiwan 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for VIZIMPRO
Location Trials
Oregon 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for VIZIMPRO

Clinical Trial Phase

Clinical Trial Phase for VIZIMPRO
Clinical Trial Phase Trials
Phase 2 4
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for VIZIMPRO
Clinical Trial Phase Trials
Recruiting 4
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for VIZIMPRO

Sponsor Name

Sponsor Name for VIZIMPRO
Sponsor Trials
Prospect Creek Foundation 1
OHSU Knight Cancer Institute 1
Pfizer 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for VIZIMPRO
Sponsor Trials
Other 7
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.